Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.
Novartis' drug ianalumab meets Phase III endpoints in Sjögren's disease trials, potentially offering the first targeted therapy for this chronic autoimmune disorder.